Expert Opinion on Pharmacotherapy最新文献_第7页

Improving pharmacokinetic/pharmacodynamic outcomes of antimicrobial therapy for pneumonia in the ICU. 改善重症监护病房肺炎抗菌治疗的药代动力学/药效学结果。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-12-01 Epub Date: 2024-12-03 DOI: 10.1080/14656566.2024.2432478

Michael Thy, Sophie Magréault, Jean-Ralph Zahar, Vincent Jullien, Jean-François Timsit

{"title":"Improving pharmacokinetic/pharmacodynamic outcomes of antimicrobial therapy for pneumonia in the ICU.","authors":"Michael Thy, Sophie Magréault, Jean-Ralph Zahar, Vincent Jullien, Jean-François Timsit","doi":"10.1080/14656566.2024.2432478","DOIUrl":"10.1080/14656566.2024.2432478","url":null,"abstract":"Introduction: Pneumonia remains a significant global health challenge due to its high prevalence and mortality rate, and challenging treatment. This review explores the best strategies to optimize the antibiotic therapy for pneumonia in critically ill patients, focusing on pharmacokinetics, pharmacodynamics, and therapeutic data.Areas covered: A review of scientific publications on severe pneumonia highlights the challenges of optimizing antibiotic use to improve lung diffusion, bacterial killing, and achieving PK/PD targets, emphasizing the need to understand microbiological epidemiology and MIC breakpoints. Key strategies like nebulization, therapeutic drug monitoring, and emerging technologies such as ELF TDM and nanomaterial-based drug delivery systems are essential for optimizing PK/PD outcomes and addressing antimicrobial resistance.Expert opinion: Improving our understanding of pulmonary pharmacokinetics and optimizing their tissue diffusion are instrumental for achieving precision antibiotic therapy for severe pneumonia. By addressing current limitations and embracing interdisciplinary collaboration, we can pave the way for more efficient personalized approaches in infectious disease management.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2347-2365"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relugolix for the treatment of prostate cancer. 用于治疗前列腺癌的Relugolix。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-12-01 Epub Date: 2024-11-29 DOI: 10.1080/14656566.2024.2433602

Panagiotis Velissarios Stamatakos, Georgios Papavasileiou, Aggeliki Leventi, Athanasios Papatsoris, Aristotelis Bamias, Athanasios Dellis, Charalampos Fragkoulis

{"title":"Relugolix for the treatment of prostate cancer.","authors":"Panagiotis Velissarios Stamatakos, Georgios Papavasileiou, Aggeliki Leventi, Athanasios Papatsoris, Aristotelis Bamias, Athanasios Dellis, Charalampos Fragkoulis","doi":"10.1080/14656566.2024.2433602","DOIUrl":"10.1080/14656566.2024.2433602","url":null,"abstract":"Introduction: Androgen deprivation therapy consists of the cornerstone of prostate cancer medical treatment. Until recently, castration of hypothalamus-hypophysis-gonadal axial was based on injectable medical agents. A few years ago, a novel per os administered GnRH antagonist was approved leading testosterone to castration level. Relugolix was approved by FDA in 2020, and it is the first per os administered GnRH antagonist. The present study is a literature review of the efficacy, safety and clinical perspectives of relugolix.Areas covered: A literature narrative review was conducted using PubMed/MEDLINE, Scopus, and the Cochrane library. Studies written in English language, considering efficacy, safety and cost-effectiveness of relugolix compared with other androgen deprivation therapies were included in the review.Expert opinion: Recent studies have examined efficacy of relugolix revealing a testosterone suppression percentage of 78.4% after 48 weeks from treatment initiation. Moreover, relugolix has been associated with less major cardiovascular events as well as better rate of testosterone recovery after treatment completion compared with the GnRH agonists. However, there is no head-to-head trial comparing relugolix with injectable GnRH antagonists, so far. As a result, a trial comparing the methods of antagonists' administration should be performed in the future.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2399-2406"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults. 评估 Vonoprazan 治疗成人侵蚀性胃食管反流病和胃食管反流病相关烧心症状的效果。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-12-01 Epub Date: 2024-11-10 DOI: 10.1080/14656566.2024.2427335

Elisa Marabotto, Francesco Calabrese, Andrea Pasta, Pierfrancesco Visaggi, Nicola de Bortoli, Amir Mari, Salvatore Tolone, Matteo Ghisa, Luisa Bertin, Vincenzo Savarino, Edoardo Vincenzo Savarino

{"title":"Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults.","authors":"Elisa Marabotto, Francesco Calabrese, Andrea Pasta, Pierfrancesco Visaggi, Nicola de Bortoli, Amir Mari, Salvatore Tolone, Matteo Ghisa, Luisa Bertin, Vincenzo Savarino, Edoardo Vincenzo Savarino","doi":"10.1080/14656566.2024.2427335","DOIUrl":"10.1080/14656566.2024.2427335","url":null,"abstract":"Introduction: Gastroesophageal reflux disease (GERD) is a common debilitating chronic disease presenting in two main forms based on esophageal mucosal appearance, the erosive reflux disease (ERD) and the non-erosive reflux disease (NERD). Acid secretion is a key factor in the disease pathogenesis and management. Potent acid-suppressant drugs have been manufactured since the mid of 1970s, initially with histamine-H2-receptors antagonists, and later, inhibitors of the proton pump (H+-K+-ATPase).More recently, potassium-competitive acid blockers (p-CABs), particularlyVonoprazan, have been introduced. Vonoprazan has shown high efficacy and safety profiles and exhibits several advantages that allow to overcome shortcomings of proton pump inhibitors (PPIs).Areas covered: In this review, we provide an updated summary of Vonoprazan pharmacodynamics and its role in clinical practice for the management of erosive esophagitis and GERD-related heartburn. Moreover, we discuss characteristics of Vonoprazan that allow to bypass some limitations of the older PPIs.Expert opinion: Long-term safety and efficacy of Vonoprazan have already been demonstrated for the induction and maintenance of ERD, preventing nocturnal acid breakthrough, reducing reflux symptoms in non-responder to standard therapy. Ongoing and future studies are expected to further elucidate its long-term benefits and potential applications in other acid-related disorders.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2319-2325"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic-associated steatotic liver disease and hepatocellular carcinoma. 代谢相关性脂肪肝和肝细胞癌。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-12-01 Epub Date: 2024-11-10 DOI: 10.1080/14656566.2024.2426680

Giovanni Catalano, Odysseas P Chatzipanagiotou, Jun Kawashima, Timothy M Pawlik

{"title":"Metabolic-associated steatotic liver disease and hepatocellular carcinoma.","authors":"Giovanni Catalano, Odysseas P Chatzipanagiotou, Jun Kawashima, Timothy M Pawlik","doi":"10.1080/14656566.2024.2426680","DOIUrl":"10.1080/14656566.2024.2426680","url":null,"abstract":"Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has been introduced as a superior term to describe steatosis on a background of metabolic dysregulation and is slated to become the leading cause of HCC worldwide, as the incidence of metabolic comorbidities is increasing. As such, MASLD has evolved into an important public health issue, potentially leading to higher rates of liver mortality and end-stage liver disease. To this end, understanding the association between MASLD and HCC may allow for the identification of better interventions and novel therapeutic strategies.Areas covered: The authors provide a review of current knowledge on HCC development among patients with MASLD, with insights into molecular pathways and current and future therapeutic strategies.Expert opinion: MASLD has a strong association with the risk of HCC development, as metabolic comorbidities induce dysregulation in molecular pathways, leading to insulin-resistance, oxidative stress, and chronic inflammation, thus causing progression to cirrhosis and eventually to HCC. Therapeutic strategies focused on reducing diabetes-associated complications, as well as the prevalence of obesity and smoking can improve patient outcomes and reduce HCC incidence. Future studies on the molecular background of metabolic alterations may help devise new therapeutic approaches aiming to improve the current management of MASLD-HCC.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2283-2291"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric pharmacotherapy: a challenge with complex roots. 儿科药物治疗：根源复杂的挑战。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-12-01 Epub Date: 2024-10-13 DOI: 10.1080/14656566.2024.2415700

Klaus Rose

引用次数: 0

Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria. 治疗阵发性夜间血红蛋白尿的色甘平。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-12-01 Epub Date: 2024-10-15 DOI: 10.1080/14656566.2024.2404110

Carlos M de Castro, Bhumika J Patel

{"title":"Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.","authors":"Carlos M de Castro, Bhumika J Patel","doi":"10.1080/14656566.2024.2404110","DOIUrl":"10.1080/14656566.2024.2404110","url":null,"abstract":"Introduction: Standard-of-care first-line treatments for paroxysmal nocturnal hemoglobinuria (PNH) include the anti-C5 therapies eculizumab and ravulizumab. However, persistent anemia, likely due to extravascular hemolysis, and reduced quality of life (QoL) due to frequent infusions remain concerns. Iptacopan is a first-in-class oral proximal complement inhibitor that targets factor B in the alternative pathway (upstream of C5), limiting intravascular and extravascular hemolysis.Areas covered: In patients previously treated with anti-C5 therapies or naive to complement inhibitors, iptacopan 200 mg twice daily resulted in clinically meaningful results in the pivotal phase 3 APPLY-PNH (NCT04558918) and APPOINT-PNH (NCT04820530) trials. Treatment with iptacopan was safe, and no treatment-related adverse events led to discontinuation.Expert opinion: APPLY-PNH and APPOINT-PNH reported clinically meaningful improvements in hemoglobin, bilirubin, and lactate dehydrogenase levels; transfusion avoidance; reticulocyte count; and fatigue. Iptacopan's safety profile was comparable to other complement inhibitors. Oral iptacopan therapy allows patients to avoid infusions, limit clinical visits, decrease medical costs, improve anemia that persists with other complement inhibitors, and improve QoL. Long-term follow-up will further assess infections, thrombosis, and breakthrough hemolysis. Before treatment, physicians need to discuss current therapeutic options with patients for shared decision-making. Guidelines are being created to assist healthcare professionals in this advancing field.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2331-2339"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reassessing the role of aspirin in patients with coronary artery disease. 重新评估阿司匹林在冠心病患者中的作用。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-12-01 Epub Date: 2024-11-10 DOI: 10.1080/14656566.2024.2427338

Udaya S Tantry, Richard C Becker, Sahib Singh, Lekshminarayan Raghavakurup, Eliano Navarese, Kevin P Bliden, Paul A Gurbel

{"title":"Reassessing the role of aspirin in patients with coronary artery disease.","authors":"Udaya S Tantry, Richard C Becker, Sahib Singh, Lekshminarayan Raghavakurup, Eliano Navarese, Kevin P Bliden, Paul A Gurbel","doi":"10.1080/14656566.2024.2427338","DOIUrl":"10.1080/14656566.2024.2427338","url":null,"abstract":"Introduction: Recent data question the use of aspirin as a bedrock of antiplatelet therapy in patients with arterial diseases. There are controversies regarding the efficacy of aspirin therapy with respect to specific demographic characteristics, dose and formulations, benefit in primary prevention, and duration in secondary prevention. Importantly, to balance the ischemic benefits and the risk of excessive bleeding following a coronary event, recent studies have investigated strategies to discontinue aspirin therapy and continue with P2Y12 receptor inhibitor monotherapy. However, the precise time when to discontinue aspirin is still unresolved.Areas covered: Evidence from recent studies evaluating the role of aspirin in primary and secondary prevention studies was collected from a selective literature search. In this review, the authors discuss current recommendations, large-scale studies of aspirin therapy, controversies, and potential future opportunities for aspirin therapy.Expert opinion: With the new evidence showing lower bleeding risk with aspirin-free strategies in both primary and secondary prevention studies, the role of aspirin is being revaluated with P2Y12 receptor inhibitor monotherapy. The potential benefits of novel aspirin formulations and alternative delivery methods, such as inhaled aspirin, are undergoing much-needed investigation with the goal of optimizing care for a wide range of patients.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2307-2317"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment. 研究尼罗加司他对需要系统治疗的进展期类脂膜瘤成人患者的疗效。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.1080/14656566.2024.2418416

Fernando Campos, Bernd Kasper

{"title":"Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment.","authors":"Fernando Campos, Bernd Kasper","doi":"10.1080/14656566.2024.2418416","DOIUrl":"10.1080/14656566.2024.2418416","url":null,"abstract":"Introduction: Desmoid tumor (DT) is a rare, locally aggressive, mesenchymal neoplasm that can arise at any site in the body. Medical therapies play a major role for DT's patients requiring treatment. A novel systemic approach has recently emerged with Nirogacestat, a γ-secretase inhibitor targeting the NOTCH signaling pathway.Areas covered: Nirogacestat is the first drug in its class to receive approval from the Food and Drug Administration (FDA) and is the first FDA-approved treatment specifically for DTs. We reviewed the data leading to its discovery, including its mechanism of action, pharmacological properties, clinical efficacy, and its positioning within the current treatment armamentarium for DTs.Expert opinion: High-quality evidence for systemic therapies in the management of DTs remains an unmet need. Nirogacestat now joins sorafenib as the only drugs with efficacy in DTs demonstrated by randomized phase 3 studies. Currently, there are no comparative trials of the available systemic therapies. Therefore, physicians should consider factors such as drug accessibility, cost, toxicity profile, comorbidities, and patient preferences when selecting treatment. Long-term efficacy and safety data will be essential for evaluating the duration of treatment response and monitoring late-onset side effects of Nirogacestat.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2115-2124"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological and non-pharmacological management of sleep disturbances in Parkinson's disease: if when and how. 帕金森病患者睡眠障碍的药物和非药物治疗：如果、何时以及如何治疗。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-11-13 DOI: 10.1080/14656566.2024.2422004

Cristian Falup-Pecurariu, Maria-Lucia Muntean, Larisa Ungureanu, Iulia Murasan, Karolina Popławska-Domaszewicz, Kallol Ray Chaudhuri, Stefania Diaconu

{"title":"Pharmacological and non-pharmacological management of sleep disturbances in Parkinson's disease: if when and how.","authors":"Cristian Falup-Pecurariu, Maria-Lucia Muntean, Larisa Ungureanu, Iulia Murasan, Karolina Popławska-Domaszewicz, Kallol Ray Chaudhuri, Stefania Diaconu","doi":"10.1080/14656566.2024.2422004","DOIUrl":"10.1080/14656566.2024.2422004","url":null,"abstract":"Introduction: Sleep dysfunction occurs in various forms and is a bothersome and intrusive non-motor symptom of Parkinson's disease (PD). Frequently undiagnosed, their poor management can have a great impact on the quality of life of PD patients and their caregivers.Areas covered: This article covers the safety and efficacy of pharmacological strategies for the management of the most frequent sleep disturbances in Parkinson's disease. Non-pharmacological aspects are also discussed, but these are not the main focus. Literature searches using electronic databases (Medline, Cochrane Library) and systematic checking of references from review articles/other reports were performed.Expert opinion: Melatonin and clonazepam are the most commonly used therapies for the management of REM sleep behavior disorder (RBD). The most used pharmacological wake-promoting agents in the treatment of excessive daytime sleepiness (EDS) are modafinil and caffeine. Poor nocturnal sleep quality is usually linked to EDS, thus proper sleep hygiene is recommended. As nocturnal motor symptoms are commonly associated with sleep fragmentation and early morning off, optimization of dopaminergic treatment during nighttime is highly recommended for the proper management of insomnia. Further interventions include eszopiclone and melatonin for the management of insomnia. Therapeutic options for restless legs syndrome (RLS) include calcium channel alpha-2-delta ligands and low-dose dopamine agonists (DA). Further confirmatory evidence is needed before the general recommendation of these treatments.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2135-2149"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent developments in drug treatment strategies for infertility in patients with polycystic ovary syndrome. 多囊卵巢综合征患者不孕症药物治疗策略的最新进展。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-20 DOI: 10.1080/14656566.2024.2418985

Stefano Palomba, Marianna Molinaro, Alice Ingargiola, Antonio Aversa

{"title":"Recent developments in drug treatment strategies for infertility in patients with polycystic ovary syndrome.","authors":"Stefano Palomba, Marianna Molinaro, Alice Ingargiola, Antonio Aversa","doi":"10.1080/14656566.2024.2418985","DOIUrl":"10.1080/14656566.2024.2418985","url":null,"abstract":"Introduction: Infertility related to polycystic ovary syndrome (PCOS) represents a significant challenge for women of reproductive age. Over the last few years, evidence-based medicine has driven new approaches for treating infertility in patients with PCOS, changing rapidly and deeply the clinical practice.Areas covered: The authors provide an in-depth examination of recent developments in drug treatment strategies that have impacted the clinical practice and changed the previous approach to infertility in patients with PCOS.Expert opinion: The authors identify four primary areas of interest that have impacted clinical practice in the last few years. Specifically, they discuss the current role of metformin administration in women with PCOS and infertility, the choice for using clomiphene citrate or letrozole as first-line treatment for ovulation induction, the use of new gonadotropin formulations for in vitro fertilization (IVF) program, and the elective embryo transfer in IVF cycles as golden standard treatment for patients with PCOS at high-risk for ovarian hyperstimulation syndrome.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2191-2202"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0